Exavir Therapeutics announces the publication of preclinical data for the ultra-long-acting integrase inhibitor XVIR-110 in Nature Communications, affirming its unique pharmacokinetic profile and potential as a best-in-class yearly antiretroviral
June 08, 2021 07:00 ET | Exavir Therapeutics
With a single administration, XVIR-110, a nano-formulated prodrug integrase inhibitor, provided year-long plasma drug levels sufficient for HIV treatment and prophylaxis in animal models Studies...
22157.jpg
Global HIV Drugs Market Report 2021-2030: Focus on NRT's, NNRT's, Protease Inhibitors, Integrate Inhibitors, Fusion Inhibitors, & Chemokine Receptor Inhibitors
May 11, 2021 05:28 ET | Research and Markets
Dublin, May 11, 2021 (GLOBE NEWSWIRE) -- The "HIV Drugs Global Market Report 2021: COVID-19 Implications and Growth to 2030" report has been added to ResearchAndMarkets.com's offering. Major players...
22157.jpg
Global Human Immunodeficiency Virus (HIV) Therapeutics Drug Forecast and Market Analysis to 2029
March 10, 2021 08:23 ET | Research and Markets
Dublin, March 10, 2021 (GLOBE NEWSWIRE) -- The "Human Immunodeficiency Virus (HIV) Therapeutics - Global Drug Forecast and Market Analysis to 2029" report has been added to ResearchAndMarkets.com's...
22157.jpg
United States HIV Infection Drug Market Report 2021-2026: Success Rate Associated with the Available Anti-retrovirals are Continuing to Expand at Historic Levels
February 24, 2021 08:03 ET | Research and Markets
Dublin, Feb. 24, 2021 (GLOBE NEWSWIRE) -- The "US HIV Infection Drug Market, Dosage, Price, Sales Insight 2021 - 2026" report has been added to ResearchAndMarkets.com's offering. "US HIV...